Russo Isabella, Penna Claudia, Musso Tiziana, Popara Jasmin, Alloatti Giuseppe, Cavalot Franco, Pagliaro Pasquale
Department of Clinical and Biological Sciences, University of Turin, 10043, Orbassano, TO, Italy.
Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.
Cardiovasc Diabetol. 2017 May 31;16(1):71. doi: 10.1186/s12933-017-0550-6.
Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet drugs, coronary diseases and ischemia/reperfusion injury, especially in diabetic conditions. Here we briefly summarize features of antiplatelet therapy in type 2 diabetes (T2DM). We also treat the influence of T2DM on ischemia/reperfusion injury and how anti-platelet therapies affect post-ischemic myocardial damage through pleiotropic properties not related to their anti-aggregating effects. miRNA-based signature associated with T2DM and its cardiovascular disease complications are also briefly considered. Influence of anti-platelet therapies and different effects of healthy and diabetic platelets on ischemia/reperfusion injury need to be further clarified in order to enhance patient benefits from antiplatelet therapy and revascularization. Here we provide insight on the difficulty to reduce the cardiovascular risk in diabetic patients and report novel information on the cardioprotective role of widely used anti-aggregant drugs.
缺血/再灌注损伤发病机制特别复杂、多因素且高度相互关联。血小板功能、抗血小板药物、冠状动脉疾病和缺血/再灌注损伤之间也正在出现复杂且相互交织的相互作用，尤其是在糖尿病情况下。在此，我们简要总结2型糖尿病（T2DM）抗血小板治疗的特点。我们还探讨了T2DM对缺血/再灌注损伤的影响，以及抗血小板治疗如何通过与其抗聚集作用无关的多效性特性影响缺血后心肌损伤。还简要考虑了与T2DM及其心血管疾病并发症相关的基于miRNA的特征。为了提高患者从抗血小板治疗和血管重建中获得的益处，抗血小板治疗的影响以及健康和糖尿病血小板对缺血/再灌注损伤的不同作用需要进一步阐明。在此，我们深入探讨降低糖尿病患者心血管风险的困难，并报告广泛使用的抗聚集药物心脏保护作用的新信息。
